A number of other research analysts have also recently commented on GSK. Kepler Capital Markets upped their price target on GlaxoSmithKline from GBX 1,360 ($18.79) to GBX 1,400 ($19.34) and gave the company a hold rating in a research report on Wednesday. Goldman Sachs set a GBX 1,750 ($24.18) price target on GlaxoSmithKline and gave the company a buy rating in a research report on Friday, March 23rd. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline in a research report on Friday, March 23rd. JPMorgan Chase & Co. reiterated a neutral rating on shares of GlaxoSmithKline in a research note on Friday, March 23rd. Finally, Liberum Capital reiterated a buy rating and set a GBX 1,630 ($22.52) price objective on shares of GlaxoSmithKline in a research note on Thursday, March 22nd. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the stock. GlaxoSmithKline currently has an average rating of Hold and a consensus price target of GBX 1,541.82 ($21.30).
Shares of LON GSK opened at GBX 1,394 ($19.26) on Wednesday. GlaxoSmithKline has a one year low of GBX 1,235.20 ($17.07) and a one year high of GBX 1,724.50 ($23.83).
In other news, insider Sir Roy Anderson acquired 562 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.66) per share, for a total transaction of £7,182.36 ($9,923.13). Also, insider Patrick Vallance sold 14,022 shares of the company’s stock in a transaction dated Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.21), for a total value of £184,809.96 ($255,332.91). Over the last 90 days, insiders acquired 591 shares of company stock worth $756,678 and sold 23,765 shares worth $31,152,709.
TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/03/31/glaxosmithkline-gsk-given-a-gbx-1400-price-target-by-morgan-stanley-analysts.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.